Non-clinical specialized CRO (non-clinical trial specialized contract research organization) Seoul Bio C&V (CEO Lee Seong-kwon) announced on the 30th that it signed a business agreement (MOU) with the 'Zhengzhou University Safety Assessment Institute' in China to strengthen cooperation and research exchange in bio-safety technology. Through the agreement, the company plans to seek cooperation in efficacy and non-clinical trial technology and support non-clinical trial data for companies entering the markets of both countries.
This agreement was signed at Zhengzhou University in China, and the participants included the CEO and executives of Seoul Bio C&V, Dr. Sang-Seop Han, the president of the Korea Biotechnology Research Association Academy, the director of the Office of External Cooperation at Zhengzhou University, the director of the Safety Evaluation Research Institute, and researchers.
After the agreement, the two organizations agreed to promote ▲joint research and development through safety and efficacy evaluation of pharmaceutical products derived from biological substances, ▲technology exchange through seminars and workshops, ▲mutual cooperation to support commercialization of biomaterial research and development, ▲strengthening cooperation in the development of primate-related disease models and pharmaceutical efficacy (PK) testing, and ▲cooperation in supporting all matters related to non-clinical data for mutual market entry by companies from both countries. Based on the non-clinical research infrastructure between Korea and China, the two organizations plan to establish a full-cycle new drug (biopharmaceutical) development cooperation system to support market entry by companies from both countries.
The agreement partner, Zhengzhou University Institute of Safety Evaluation, is located in the geographical center of mainland China and is the only university institution in China that possesses a one-stop service system for new drug development education, material development, non-clinical, clinical, and licensing, and also has a primate center. It is growing with the goal of playing a central role in the Chinese and global bio markets.
Seoul Bio C&V and Zhengzhou University in China plan to mutually support non-clinical trials and R&D to promote the development of biopharmaceuticals from biological substances by Korean and Chinese companies and their entry into the bilateral and global markets. In addition, they plan to conduct a wide range of PK tests and efficacy evaluations using various animal models including primates to support strengthening the competitiveness of companies through rapid product commercialization, reduction of research costs, and shortened testing periods based on non-clinical trials.
In addition, the two companies plan to subdivide areas of cooperation through regular exchanges between practitioners and joint workshops, and to work together on follow-up projects for the industrialization and global expansion of research results.
Seoul Bio C&V CEO Lee Seong-kwon said, “This agreement will be a new model for cooperation in the development of new biopharmaceuticals using biological substances between the two countries. By combining our research capabilities with Jeongju University’s non-clinical infrastructure, we will support the market entry of companies from both countries and strive to achieve meaningful results that contribute to the health of the people of both countries.”
Meanwhile, Seoul Bio C&V is prioritizing the provision of highly reliable non-clinical research services through collaboration on efficacy and safety evaluation technologies using various animal models, and is preparing to obtain accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC-I) and meet the licensing requirements related to securing global reliability.
- See more related articles
You must be logged in to post a comment.